Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study
Ryan J. Hartmaier(AstraZeneca (United States)), Zofia Piotrowska(Global Cancer Institute), Sarah B. Goldberg(Yale University), Jonathan H. Goldman(University of California, Los Angeles), Aleksandra Markovets(AstraZeneca (United States)), Byoung Chul Cho(Yonsei University), Adrianus J. de Langen(The Netherlands Cancer Institute), Isamu Okamoto(Kyushu University Hospital), Jonathan W. Riess(University of California Davis Medical Center), Xiuning Le(The University of Texas MD Anderson Cancer Center), Jan Cosaert(AstraZeneca (United Kingdom)), Helena A. Yu(Memorial Sloan Kettering Cancer Center)
Cited by 12
Related Papers
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k